June 6, 2018 – Janesville, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that it will host a key opinion leader (KOL) meeting on the topic of Nuclear Medicine and Diagnostics on June 15th in New York City.
The event will feature a presentation by key opinion leader Ira N. Goldman, of Lantheus Medical Imaging, who will discuss the current manufacturing and supply chain landscape for medical isotopes that are commonly used in nuclear medicine and cancer diagnostics. Mr. Goldman will be available to answer questions at the conclusion of the event.
The management team from SHINE Medical Technologies will provide an overview of the company’s medical isotope production business, including their patented, proprietary manufacturing process to produce medical tracers and cancer treatment elements for nuclear medicine. The SHINE technology offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the existing global supply chain for molybdenum-99.
Ira N. Goldman is Senior Director, Global Strategic Supply and Government Relations, Lantheus Medical Imaging (LMI). He is Chairman of the Security of Supply Working Group, Association of Imaging Producers and Equipment Suppliers (European Industrial Association for Nuclear Medicine and Molecular Imaging), and Co-Chairman of the Isotope Supply Committee, Council on Radioisotopes and Radiopharmaceuticals (CORAR). Mr. Goldman is responsible for corporate strategy for a globally diversified and reliable supply of Mo-99 and Xe-133. He is also responsible for Lantheus strategy and actions for Government and Congressional relations and provides expert advice to corporate new business development for medical radioisotopes. Mr. Goldman had previous professional positions at the International Atomic Energy Agency, Vienna, Austria; the U.S. Mission to International Organizations, Vienna, Austria; the U.S. Department of Energy, the U.S. Department of State and the Congressional Research Service of the Library of Congress, Washington, D.C.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. For those who are unable to attend in person, a live webcast and replay of the event will be accessible here.
Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium-99m (Tc-99m). Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including Mo‑99.
About SHINE Medical Technologies, Inc.
Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for molybdenum-99. In 2014, SHINE announced the execution of molybdenum-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE molybdenum-99 can act as a drop-in replacement for reactor-based moly-99. In 2016, SHINE received regulatory approval to construct its facility from the Nuclear Regulatory Commission and signed a moly-99 supply agreement with HTA Co., Ltd., the largest Chinese distributor of radiopharmaceuticals. Learn more at http://shinemed.com.